-
公开(公告)号：US11660311B2
公开(公告)日：2023-05-30
申请号：US16754301
申请日：2018-10-09
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Brian E. Fink , Dharmpal S. Dodd , Yufen Zhao , Lan-Ying Qin , Zheming Ruan , Lalgudi S. Harikrishnan , Muthoni G. Kamau
IPC: C07H21/04 , A61K31/7084 , A61K39/395
CPC classification number: A61K31/7084 , A61K39/3955 , C07H21/04
Abstract: The present invention is directed to compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
-
公开(公告)号：US09492460B2
公开(公告)日：2016-11-15
申请号：US14190477
申请日：2014-02-26
Applicant: Bristol-Myers Squibb Company
Inventor： Michael A. Poss , David R. Tortolani , Dharmpal S. Dodd , Christopher P. Mussari , John S. Tokarski , Ashvinikumar V. Gavai , Yufen Zhao , George V. Delucca , Daniel O'Malley , Derek J. Norris , Patrice Gill , Claude A. Quesnelle , Wen-Ching Han
IPC: C07D405/14 , C07D413/14 , C07D417/14 , A61K31/553 , C07D413/04 , A61K31/4192 , A61K31/422 , A61K31/427 , A61K31/454 , A61K31/496 , A61K31/5355 , A61K31/5377 , A61K31/541
CPC classification number: A61K31/553 , A61K31/4192 , A61K31/422 , A61K31/427 , A61K31/454 , A61K31/496 , A61K31/5355 , A61K31/5377 , A61K31/541 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14
Abstract: The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
Abstract translation: 本发明涉及咔唑化合物，包含本发明化合物的药学上可接受的组合物和使用所述组合物治疗各种疾病的方法。
-
公开(公告)号：US20160176871A1
公开(公告)日：2016-06-23
申请号：US14977709
申请日：2015-12-22
Applicant: Bristol-Myers Squibb Company
Inventor： Brian E. Fink , Yufen Zhao , Robert M. Borzilleri , Liping Zhang , Kyoung S. Kim , Muthoni G. Kamau , Andrew J. Tebben
IPC: C07D471/04 , A61K31/506 , A61K31/4709 , A61K31/501 , A61K31/4985 , A61K31/5377 , A61K31/496 , A61K31/541 , A61K31/437 , C07D487/04
CPC classification number: C07D471/04 , A61K31/437 , A61K31/4709 , A61K31/496 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/541 , C07D487/04 , Y02P20/582
Abstract: The invention relates generally to compounds that modulate the activity of TGFβR-1 and TGFβR-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
Abstract translation: 本发明一般涉及调节TGF-bgr R-1和TGF-bgr R-2的活性的化合物，含有所述化合物的药物组合物和使用本发明化合物治疗增殖性疾病和失调性细胞凋亡障碍（例如癌症）的方法 。
-
公开(公告)号：US09371328B2
公开(公告)日：2016-06-21
申请号：US14191861
申请日：2014-02-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Brian E. Fink , Libing Chen , Ashvinikumar V. Gavai , Liqi He , Soong-Hoon Kim , Andrew James Nation , Yufen Zhao , Litai H. Zhang
IPC: C07D487/04 , C07D498/04
CPC classification number: C07D487/04 , C07D498/04
Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐。 式（I）咪唑并哒嗪抑制蛋白激酶活性，从而使其成为抗癌剂。
-
公开(公告)号：US09242941B2
公开(公告)日：2016-01-26
申请号：US14429935
申请日：2013-09-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Ashvinikumar V. Gavai , Yufen Zhao , Daniel O'Malley , Claude A. Quesnelle , Brian E. Fink , Derek J. Norris , Wen-Ching Han , George V. DeLucca
IPC: C07D401/04 , C07D243/24 , C07F9/12 , C07F9/645 , A61K31/5513 , A61K31/675 , A61K45/06 , C07D403/12
CPC classification number: C07D243/24 , A61K31/5513 , A61K31/675 , A61K45/06 , C07D401/04 , C07D401/12 , C07D403/12 , C07F9/12 , C07F9/645
Abstract: Disclosed are compounds of Formula (I) and/or salts thereof: (I) wherein: R1 is CH2CH2CF3; R2 is CH2(cyclopropyl), CH(CH3)(cyclopropyl), or CH2CH2CH3; R3 is H, CH3, or Rx; R4 is H or Ry; and Rx, Ry, Ra, Rb, Rc, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer. The compounds of Formula (I) also include prodrugs of the Notch inhibitor compounds.
Abstract translation: 公开了式（I）和/或其盐的化合物：（I）其中：R 1是CH 2 CH 2 CF 3; R2是CH2（环丙基），CH（CH3）（环丙基）或CH2CH2CH3; R3是H，CH3或Rx; R4是H或Ry; 并且Rx，Ry，Ra，Rb，Rc，y和z在本文中定义。 还公开了使用这些化合物抑制Notch受体的方法，以及包含这些化合物的药物组合物。 这些化合物可用于治疗，预防或减缓各种治疗领域（例如癌症）中疾病或病症的发展。 式（I）的化合物还包括Notch抑制剂化合物的前药。
-
Patent Agency Ranking
公开(公告)号：US20150210697A1
公开(公告)日：2015-07-30
申请号：US14414152
申请日：2013-07-12
Applicant: Bristol-Myers Squibb Company
Inventor： Ashok Vinayak Purandare , Brian E. Fink , Walter Lewis Johnson , Amy C. Hart , Liqi He , Tram N. Huynh , Jennifer Inghrim , Harold Mastalerz , Xiaopeng Sang , Christine M. Tarby , Honghe Wan , Wayne Vaccaro , Guifen Zhang , Yufen Zhao , Kurt Zimmermann , Yong Zhang , Libing Chen , Bin Chen , John S. Tokarski , Ashvinikumar V. Gavai
IPC: C07D487/04 , C07F7/18 , C07D487/10 , C07D487/08 , C07D471/10
CPC classification number: C07D487/04 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K31/541 , A61K31/55 , A61K31/551 , A61K31/675 , A61K45/06 , C07D471/10 , C07D487/08 , C07D487/10 , C07D487/22 , C07D498/04 , C07D519/00 , C07F7/1804 , C07F9/6521 , C07F9/6561 , C07F9/65616
Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
-
公开(公告)号：US08940736B2
公开(公告)日：2015-01-27
申请号：US13940619
申请日：2013-07-12
Applicant: Bristol-Myers Squibb Company
Inventor： Ashok Vinayak Purandare , Brian E. Fink , Ashvinikumar V. Gavai , Walter Lewis Johnson , Amy C. Hart , Liqi He , Tram N. Huynh , Jennifer Inghrim , Harold Mastalerz , Xiaopeng Sang , Christine M. Tarby , Honghe Wan , Wayne Vaccaro , Guifen Zhang , Yufen Zhao , Kurt Zimmermann
IPC: A61K31/535 , A01N43/00 , A61K31/00 , A01N57/00 , A61K31/675 , C07D413/00 , C07D487/00 , C07D243/08 , A61K31/53 , A61K45/06 , A61K31/5377 , C07D471/10 , C07D487/10 , C07D498/04 , A61K31/551 , C07D487/04 , A61K31/5383 , C07F9/6521
CPC classification number: C07D487/04 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K31/541 , A61K31/55 , A61K31/551 , A61K31/675 , A61K45/06 , C07D471/10 , C07D487/08 , C07D487/10 , C07D487/22 , C07D498/04 , C07D519/00 , C07F7/1804 , C07F9/6521 , C07F9/6561 , C07F9/65616
Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐。 式（I）咪唑三嗪抑制蛋白激酶活性，从而使它们用作抗癌剂。
-
公开(公告)号：US20140018319A1
公开(公告)日：2014-01-16
申请号：US13940619
申请日：2013-07-12
Applicant: Bristol-Myers Squibb Company
Inventor： Ashok Vinayak Purandare , Brian E. Fink , Ashvinikumar V. Gavai , Walter Lewis Johnson , Amy C. Hart , Liqi He , Tram N. Huynh , Jennifer Inghrim , Harold Mastalerz , Xiaopeng Sang , Christine M. Tarby , Honghe Wan , Wayne Vaccaro , Guifen Zhang , Yufen Zhao , Kurt Zimmermann
IPC: A61K31/675 , A61K31/53 , A61K31/551 , A61K31/5377 , C07D487/10 , C07F9/6521 , C07D498/04 , A61K31/5383 , A61K45/06 , C07D487/04 , C07D471/10
CPC classification number: C07D487/04 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K31/541 , A61K31/55 , A61K31/551 , A61K31/675 , A61K45/06 , C07D471/10 , C07D487/08 , C07D487/10 , C07D487/22 , C07D498/04 , C07D519/00 , C07F7/1804 , C07F9/6521 , C07F9/6561 , C07F9/65616
Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐。 式（I）咪唑三嗪抑制蛋白激酶活性，从而使它们用作抗癌剂。
-
公开(公告)号：US11427610B2
公开(公告)日：2022-08-30
申请号：US16849091
申请日：2018-10-16
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Brian E. Fink , Yufen Zhao , Libing Chen , Audris Huang
Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
-
公开(公告)号：US10519187B2
公开(公告)日：2019-12-31
申请号：US16272172
申请日：2019-02-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Brian E. Fink , Dharmpal S. Dodd , Steven J. Walker , Libing Chen , Yufen Zhao , Zheming Ruan , Lan-Ying Qin , Peter Kinam Park , Muthoni G. Kamau , Lalgudi S. Harikrishnan
IPC: C07H19/213 , A61P35/00 , C07K16/28
Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
-
-
-
-
-
-
-
-
-
Search Results
31
records
(took 0.065 seconds)
